Related Experiment Video
Updated: Mar 14, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic lethality in lung cancer and translation to clinical therapies
Ada W Y Leung1,2, Tanya de Silva3,4, Marcel B Bally5,3,6,7
1Experimental Therapeutics, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada. aleung@bccrc.ca.
Abstract:
Lung cancer is a heterogeneous disease consisting of multiple histological subtypes each driven by unique genetic alterations. Despite the development of targeted therapies that inhibit the oncogenic mutations driving a subset of lung cancer cases, there is a paucity of effective treatments for the majority of lung cancer patients and new strategies are urgently needed. In recent years, the concept of synthetic lethality has been established as an effective approach for discovering novel cancer-specific targets as well as a method to improve the efficacy of existing drugs which provide partial but insufficient benefits for patients. In this review, we discuss the concept of synthetic lethality, the various types of synthetic lethal interactions in the context of oncology and the approaches used to identify these interactions, including recent advances that have transformed the ability to discover novel synthetic lethal combinations on a global scale. Lastly, we describe the specific synthetic lethal interactions identified in lung cancer to date and explore the pharmacological challenges and considerations in translating these discoveries to the clinic.
Insights
Synthetic lethality offers a promising strategy for lung cancer treatment by targeting cancer-specific vulnerabilities. This approach aims to develop new therapies for patients with limited options, addressing the heterogeneity of lung cancer.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Lung cancer is a complex disease with diverse histological subtypes and genetic drivers.
- Current targeted therapies benefit only a subset of patients, highlighting the need for novel treatment strategies.
- Synthetic lethality presents a promising avenue for discovering new cancer-specific targets and enhancing existing treatments.
Approach:
- Reviewing the fundamental concept of synthetic lethality and its application in oncology.
- Exploring various types of synthetic lethal interactions and methodologies for their identification.
- Highlighting recent technological advancements in discovering synthetic lethal combinations.
Key Points:
- Synthetic lethality involves genetic interactions where the simultaneous disruption of two or more genes leads to cell death.
- This approach exploits differences between cancer cells and normal cells to achieve selective toxicity.
- Advances in high-throughput screening and computational methods accelerate the discovery of synthetic lethal interactions.
Conclusions:
- Specific synthetic lethal interactions have been identified in lung cancer, offering potential therapeutic targets.
- Translating these discoveries into effective clinical treatments faces pharmacological challenges and requires careful consideration.
- Further research is crucial to optimize synthetic lethality-based therapies for lung cancer patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase